Mount Sinai's Knowledge Management Center for Illuminating the Druggable Genome

西奈山阐明可药物基因组的知识管理中心

基本信息

批准号：
9325632
负责人：
Joel Thomas Dudley
金额：
$ 56.2万
依托单位：
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-08-01 至 2017-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9325632
关键词：
Adverse effects Architecture Attenuated Bioinformatics Biological Biology Biotechnology Classification Collaborations Communities Complex Data Data Analyses Data Collection Data Science Databases Development Disease Family Feedback Fibrosis Foundations Functional disorder Gene Proteins Gene Targeting Genes Genome Goals Imagery Individual Information Resources Management Instruction Investigation Ion Channel Kidney Kidney Diseases Knowledge Link Literature Manuals Methods Mining Mission Modality Modeling Molecular and Cellular Biology Monitor Mutation Nuclear Receptors Patients Pharmaceutical Preparations Pharmacology Phenotype Plug-in Positioning Attribute Productivity Property Protein Kinase Proteins Records Research Research Infrastructure Software Tools Source Source Code Techniques Technology Tertiary Protein Structure Testing Training Translational Research Validation Work abstracting base clinically relevant cohort data integration digital disease phenotype experience genome-wide individual patient innovation member new therapeutic target open data open source petabyte protein structure research and development search engine software development technology development tool uptake user-friendly web page web portal

项目摘要

The Knowledge Management Center for Illuminating the Druggable Genome (KMC-IDG) at Mount Sinai will assemble, organize and visualize data collected from the under-studied druggable genome from the four families: protein kinases, nuclear receptor, ion channels and GPCRs. The KMC-IDG will also attempt linking such under-studied druggable targets for their potential applications in various diseases. To achieve this we will assemble and abstract data from four domains: proteins/genes/targets, drugs/perturbagens, diseases/phenotypes/side-effects, and data from individual patients. Various pipe-lines and workflow will be established to connect clusters of patients from various diseases to under-studied druggable targets. The Ma'ayan and Dudley Labs are well positioned to carry out successfully this project based on their prior track record of productivity, foundation of source code and data that is already collected and organized, and strong existing user base that can be directed to the newly developed portal. In addition, both labs have a strong track record of collaborations including the computational identification and experimental validation of at least one under-studied protein kinase as a potential important target for attenuating kidney fibrosis. One unique and innovative research component of this project is an investigation into the sources of the literature and experimental biases that exist in the molecular and cellular biology research domains.

位于西奈山的阐明药物基因组知识管理中心 (KMC-IDG) 将组装、组织和可视化从四个未充分研究的可药物基因组中收集的数据家族：蛋白激酶、核受体、离子通道和 GPCR。 KMC-IDG 还将尝试链接这些药物靶标在各种疾病中的潜在应用尚未得到充分研究。为了实现这一目标，我们将收集和提取来自四个领域的数据：蛋白质/基因/靶标、药物/扰动物、疾病/表型/副作用，以及来自个体患者的数据。各种管道和工作流程将建立的目的是将患有各种疾病的患者群体与尚未充分研究的药物靶标联系起来。这 Ma'ayan 和 Dudley Labs 处于有利位置，可以根据之前的轨迹成功开展该项目生产力记录、已收集和组织的源代码和数据的基础，以及强大的可以将现有用户群定向到新开发的门户。此外，两个实验室都拥有强大的合作记录，包括至少以下的计算识别和实验验证一种尚未充分研究的蛋白激酶作为减轻肾纤维化的潜在重要靶标。一件独一无二的该项目的创新研究部分是对文献和文献来源的调查分子和细胞生物学研究领域中存在的实验偏差。